Vor Biopharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Vor Biopharma Inc. on August 25, 2025, covering corporate governance events occurring between August 25 and August 27, 2025. The Company is a Delaware corporation with its principal executive offices in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Global Select Market under the symbol "VOR."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on changes to the Board of Directors and does not contain financial performance data.
Material Changes
The Company reported significant changes to its Board of Directors:
- Resignations: Joshua Resnick, M.D. resigned effective August 25, 2025. Matthew Patterson and David Lubner resigned effective August 26, 2025. The Company stated these departures were not due to any disagreement with the Company.
- Appointment: Sarah Reed was appointed on August 27, 2025, to fill the vacancy created by Dr. Resnick. She serves as an independent Class II director until the 2026 annual meeting.
- Compensation: Ms. Reed will receive a $40,000 annual cash retainer and stock options to purchase 60,000 shares upon appointment, with eligibility for 30,000 additional shares annually starting in 2026.
Outlook, Risks, and Contingencies
Ms. Reed was nominated by RA Capital Management, L.P., pursuant to a securities purchase agreement dated December 26, 2024. This agreement grants RA Capital the right to appoint a director so long as it and its affiliates beneficially own at least 4.99% of the Company's outstanding common stock. The filing notes that RA Capital and its affiliates currently hold greater than 5% of the Company's voting stock. No other risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following the three resignations and one appointment.
- Confirm RA Capital Management's current beneficial ownership percentage to ensure it remains above the 4.99% threshold required for their board seat.
- Review the Company's Non-Employee Directors' Compensation Policy (referenced as Exhibit 10.1 in the 2023 10-Q) for details on equity vesting schedules.
- Check for any subsequent filings regarding the election of directors to fill the vacancies left by Mr. Patterson and Mr. Lubner.